Xi Chen
Research Subjects
Xi Chen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Qiuyan Guo
School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication - Rubing Xu
School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication - Ruqian Zhong
School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication - Shengmei Wang
The First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
1 shared publication - Xinhua Xia
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 26 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 306
Anti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms
Conventional cancer treatments often have complications and serious side effects, with limited improvements in 5-year survival and quality of life. Photothermal therapy (PTT) employs materials that convert light to heat when exposed to near-infrared light to raise the temperature of the tumor site to directly ablate tumor cells, induce immunogenic cell death, and improve the tumor microenvironment. This therapy has several benefits, including minimal invasiveness, high efficacy, reduced side effects, and robust targeting capabilities. Beyond just photothermal conversion materials, nanoplatforms significantly contribute to PTT by supplying effective photothermal conversion materials and bolstering tumor targeting to amplify anti-tumor effects. However, the anti-tumor effects of PTT alone are ultimately limited and often need to be combined with other therapies. This narrative review describes the recent progress of PTT combined with chemotherapy, radiotherapy, photodynamic therapy, immunotherapy, gene therapy, gas therapy, chemodynamic therapy, photoacoustic imaging, starvation therapy, and multimodal therapy. Studies have shown that combining PTT with other treatments can improve efficacy, reduce side effects, and overcome drug resistance. Despite the encouraging results, challenges such as optimizing treatment protocols, addressing tumor heterogeneity, and overcoming biological barriers remain. This paper highlights the potential for personalized, multimodal approaches to improve cancer treatment outcomes.
- 26 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 306
Top Cited PapersOpen AccessAnti-Tumor Strategies of Photothermal Therapy Combined with Other Therapies Using Nanoplatforms
Conventional cancer treatments often have complications and serious side effects, with limited improvements in 5-year survival and quality of life. Photothermal therapy (PTT) employs materials that convert light to heat when exposed to near-infrared light to raise the temperature of the tumor site to directly ablate tumor cells, induce immunogenic cell death, and improve the tumor microenvironment. This therapy has several benefits, including minimal invasiveness, high efficacy, reduced side effects, and robust targeting capabilities. Beyond just photothermal conversion materials, nanoplatforms significantly contribute to PTT by supplying effective photothermal conversion materials and bolstering tumor targeting to amplify anti-tumor effects. However, the anti-tumor effects of PTT alone are ultimately limited and often need to be combined with other therapies. This narrative review describes the recent progress of PTT combined with chemotherapy, radiotherapy, photodynamic therapy, immunotherapy, gene therapy, gas therapy, chemodynamic therapy, photoacoustic imaging, starvation therapy, and multimodal therapy. Studies have shown that combining PTT with other treatments can improve efficacy, reduce side effects, and overcome drug resistance. Despite the encouraging results, challenges such as optimizing treatment protocols, addressing tumor heterogeneity, and overcoming biological barriers remain. This paper highlights the potential for personalized, multimodal approaches to improve cancer treatment outcomes.